1618P Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion positive (NRG1+) pancreatic ductal adenocarcinoma (PDAC)

Alison M. Schram, Teresa Macarulla, James M. Cleary, Cindy Neuzillet, Dirk Arnold, Kim A. Reiss, Tanios Bekaii‐Saab, Jordi Rodón, Kōichi Goto, Sun Young Rha, M. Duruisseaux, Natasha B. Leighl, Benjamin A. Weinberg, M.N. Al-Hallak, Andrew K. Joe, S. Adeyemi, Ernesto Wasserman, K-J. Koeman, Alexander Drilon, Eileen M. O’Reilly